HYHui Ye

Hui Ye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hui Ye has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Jinheng Qian

    School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China

    3 shared publications
  • Leyu Wan

    School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China

    3 shared publications
  • Meiqi Li

    School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China

    3 shared publications
  • Xuanxuan Hu

    School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China

    3 shared publications
  • Yanneng Fu

    School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China

    3 shared publications
  • Yejun Zhang

    School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China

    3 shared publications

Latest Publications

  • Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer

    by Yuan Zhang, Jinheng Qian, Yanneng Fu, Zihan Wang, Wanping Hu, Jinxia Zhang, Yuexuan Wang, Yangyang Guo, Weikang Chen, Yejun Zhang, et al.


  • Open Access

    An innovative immunotherapeutic strategy for rheumatoid arthritis: Selectively suppressing angiogenesis and osteoclast differentiation by fully human antibody targeting thymocyte antigen-1

    by Xuanxuan Hu, Meiqi Li, Yu Zhang, Kanru Sang, Yejun Zhang, Wulan Li, Bo Liu, Leyu Wan, Bang Du, Jinheng Qian, et al.


  • Open Access

    An innovative immunotherapeutic strategy for rheumatoid arthritis: selectively suppressing angiogenesis and osteoclast differentiation by fully human antibody targeting thymocyte antigen-1

    by Xuanxuan Hu, Meiqi Li, Yu Zhang, Kanru Sang, Yejun Zhang, Wulan Li, Bo Liu, Leyu Wan, Bang Du, Jinheng Qian, et al.

    Background: Thymocyte antigen-1 (THY-1) is a potential therapeutic target for rheumatoid arthritis (RA) treatment, and THY-1 positive fibroblast-like synoviocytes (FLS) are enriched in the synovium of RA patients and participate in angiogenesis to accelerate rheumatoid arthritis development. In this study, we screened a full human antibody targeting THY-1 and exploring its anti-RA activity and mechanism. Methods: We screened antibody targeting THY-1 (i.e. THY-1 Ab), an antagonistic antibody from human ScFv phage antibody library, by using THY-1 as a target. After proving its binding ability with surface plasmon resonance (SPR), we explored its effect on RA based on FLS transcriptomic analysis and bioinformatics analysis tips treated with THY-1 Ab. Both in vivo and in vitro experiments have proved its effectiveness in the treatment of rheumatoid arthritis. What’s up, we clarified the mechanism of action of the scFv antibody. Results:THY-1 Ab could not only bind to human THY-1 extracellular domains, but also combine to Murine THY-1. In addition, THY-1 Ab restrained the proliferation and secretion of the proinflammatory factors. THY-1 Ab restrained angiogenesis by inhibiting VEGF expression in RA FLS, and the THY-1 Ab and RA FLS combination can effectively inhibit the differentiation of osteoclasts, which down-regulated the expression of JUNB via hsa_circ_0094342—miRNA-155-5P—SPI1 axis, thus regulating AP-1 to suppress angiogenesis and osteoclast differentiation. In Collagen induced arthritis (CIA), disease progression was effectively alleviated by THY-1 Ab. Conclusions: These findings support that THY-1 Ab is a potential drug for the rheumatoid arthritis treatment.

  • Recent advances in the aetiology of recurrent aphthous stomatitis (RAS)

    by Zihan Wang, Haibo Cao, Jianqi Xiong, Yilong Lu, Yixiao Deng, Han Nan, Shutian Zheng, Hui Ye, Zhensheng Cao

    Recurrent aphthous stomatitis (RAS) is the most common disease of oral mucosa, which almost attacks each individual once in their lifespan. Although plenty of factors have been suggested to play a role in the pathogenesis of RAS, the aetiology of RAS is still controversial, which might lead to limited clinical therapies in accordance with each RAS patient. This review mainly illustrates recent advances in potential causes associated with RAS in detail. Deeper comprehension of the aetiology of RAS will support doctors and researchers to make a better management of RAS patients and to discover new treatments. The aetiology of RAS is complicated, hence we should take a comprehensive view into its aetiology, with multiple potential factors being considered. Sample collection of RAS patients have greatly limited the progress in the aetiology of RAS. A research model of multiagency cooperation can help achieve perfect sample collection of year-round and multiposition.


  • Open Access

    A Novel Targeted Therapy System for Cervical Cancer: Co-Delivery System of Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier

    by Hui Ye, Xiaoying Chu, Zhensheng Cao, Xuanxuan Hu, Zihan Wang, Meiqi Li, Leyu Wan, Yongping Li, Yongge Cao, Zhanqiu Diao, et al.

    Background: This study was aimed to prepare a novel magnetic thermosensitive cationic liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA of MDC1 (MDC1-AS) to Cervical cancer cells and evaluate the efficiency of this drug carrier and its antitumor effects on Cervical cancer. Methods: Thermosensitive magnetic cationic liposomes were prepared using thin-film hydration method. The OXA and MDC1-AS vectors were loaded into the codelivery system, and the in vitro OXA thermosensitive release activity, efficiency of MDC1-AS regulating MDC1, in vitro cytotoxicity, and in vivo antitumor activity were determined. Results: The codelivery system had desirable targeted delivery efficacy, OXA thermosensitive release, and MDC1-AS regulating MDC1. Codelivery of OXA and MDC1-AS enhanced the inhibition of cervical cancer cell growth in vitro and in vivo, compared with single drug delivery. Conclusion: The novel codelivery of OXA and MDC1-AS magnetic thermosensitive cationic liposome drug carrier can be applied in the combined chemotherapy and gene therapy for cervical cancer.


  • Open Access

    Full high-throughput sequencing analysis of differences in expression profiles of long noncoding RNAs and their mechanisms of action in systemic lupus erythematosus

    by Hui Ye, Xue Wang, Lei Wang, Xiaoying Chu, Xuanxuan Hu, Li Sun, Minghua Jiang, Hong Wang, Zihan Wang, Han Zhao, et al.

    Background: The specific function of long noncoding RNAs (lncRNAs) in systemic lupus erythematosus (SLE) and the mechanism of their involvement in related pathological changes remain to be elucidated, so, in this study, we analyzed the differences in the expression profiles of lncRNAs and their mechanisms of action in SLE using full high-throughput sequencing, bioinformatics, etc. methods. Methods: We used high-throughput sequencing to detect differences in the expression profiles of lncRNAs, miRNAs, and mRNAs in PBMCs from patients with SLE at the genome-wide level. Next, we predicted target genes of 30 lincRNAs (long intergenic noncoding RNAs) by constructing a coexpression network of differential lincRNAs and mRNAs and identified the role of lincRNAs. Then, we analyzed the coexpression network of 23 optimized lincRNAs and their corresponding 353 miRNAs, evaluated the cis- and trans-effects of these lincRNAs, and performed GO and KEGG analyses of target genes. We also selected 8 lincRNAs and 2 newly discovered lncRNAs for q-PCR validation and lncRNA–miRNA–mRNA analysis. Finally, we also analyzed respectively the relation between lncRNAs and gender bias in SLE patients using RT-qPCR, the relation between Systemic Lupus Erythematosus Disease Activity Index score and the “IFN signature” using ELISA, and the relation between the differential expression of lncRNAs and a change in the number of a cell type of PBMCs in SLE patients using RT-qPCR. Results: The profiles of 1087 lncRNAs, 102 miRNAs, and 4101 mRNAs in PBMCs significantly differed between patients with SLE and healthy controls. The coexpression network analysis showed that the network contained 23 lincRNAs and 353 mRNAs. The evaluation of the cis- and trans-effects showed that the 23 lincRNAs acted on 704 target genes. GO and KEGG analyses of the target genes predicted the biological functions of the 23 lincRNAs. q-PCR validation showed 7 lincRNAs and 2 novel lncRNAs were identical to the sequencing results. The ceRNA network contained 7 validated lincRNAs, 15 miRNAs, and 155 mRNAs. In addition, the differential expression of lncRNAs may be gender dependent in SLE patients, SLE patients also exhibit a robust “IFN signature,” and PBMCs exhibiting differential expression of lncRNAs may be due to a change in the number of a cell type. Conclusion: This work determined specific lncRNAs that play important biological functions in the pathogenesis of lupus and provided a new direction for diagnosis and treatment of disease.


  • Open Access

    Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application

    by Hui Ye, Jiansong Tong, Jiangyi Liu, Wenman Lin, Chengshou Zhang, Kai Chen, Jie Zhao, Wenjing Zhu

    Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application